Your browser doesn't support javascript.
loading
1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3.
Christopher, John A; Atkinson, Francis L; Bax, Benjamin D; Brown, Murray J B; Champigny, Aurélie C; Chuang, Tsu Tshen; Jones, Emma J; Mosley, Julie E; Musgrave, James R.
Affiliation
  • Christopher JA; GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. john@christopher257.fsnet.co.uk
Bioorg Med Chem Lett ; 19(8): 2230-4, 2009 Apr 15.
Article in En | MEDLINE | ID: mdl-19303774
ABSTRACT
A series of 1-aryl-3,4-dihydroisoquinoline inhibitors of JNK3 are described. Compounds 20 and 24 are the most potent inhibitors (pIC50 7.3 and 6.9, respectively in a radiometric filter binding assay), with 10- and 1000-fold selectivity over JNK2 and JNK1, respectively, and selectivity within the wider mitogen-activated protein kinase (MAPK) family against p38alpha and ERK2. X-ray crystallography of 16 reveals a highly unusual binding mode where an H-bond acceptor interaction with the hinge region is made by a chloro substituent.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase 10 / Protein Kinase Inhibitors / Isoquinolines Limits: Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2009 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase 10 / Protein Kinase Inhibitors / Isoquinolines Limits: Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2009 Document type: Article Affiliation country: United kingdom